ArticleBlood advances2026
Venous thromboembolism in women on estrogen therapy: presentation, management, and outcomes in the RIETE registry.
Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Estrogen-associated thrombosis and the road not taken.Blood advances · 2026Article
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractCombined oral contraceptives increase the venous thromboembolism (VTE) risk nearly fivefold. Their widespread use translates into a substantial number of VTE events in otherwise healthy young women. However, data on estrogen-associated VTE remain limited. We used data from the RIETE registry (2011-2024), including patients without cancer <50 years with acute VTE. We analyzed the presentation, management, and outcomes in women with estrogen-associated VTE and compared them with men and women with non-estrogen-associated VTE. Among 13 418 patients, 2786 women experienced a VTE during estrogen therapy. They were younger (mean age ± standard deviation, 32 ± 9 years) than men (39 ± 8; P< .001) and other women (38 ± 8; P< .001). In 74% of estrogen-associated VTE cases, no additional transient risk factors were present. Estrogen therapy was discontinued in 92% of cases at diagnosis. The median anticoagulation duration was 6 months (interquartile range, 4-9). Bleeding during anticoagulation was more frequent in women with estrogen-associated VTE (8.70 per 100 patient-years; 95% confidence interval [CI], 7.09-10.6) and women with non-estrogen-associated VTE (11.8; 95% CI, 10.0-13.7) than in men (5.46; 95% CI, 4.64-6.39; P< .05). After stopping anticoagulation, recurrence was lowest in women with estrogen-associated VTE (2.07 per 100 patient-years; 95% CI, 1.57-2.68) compared with men (8.70; 95% CI, 7.75-9.73; P< .001) and other women (5.05; 95% CI, 4.16-6.07; P< .001). Women with VTE during estrogen therapy were younger. Bleeding during anticoagulation was more frequent among women than among men. Women with estrogen therapy-associated VTE had a low recurrence risk in the first year after stopping anticoagulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.